◀ Back to PRKAR2A

ARPP21 — PRKAR2A

Text-mined interactions from Literome

Dulubova et al., J Neurochem 2001 : In non-neuronal cells, ARPP-19 was highly phosphorylated in response to activation of PKA
Svenningsson et al., Annu Rev Pharmacol Toxicol 2004 (Synaptic Transmission) : Dopamine- and cAMP regulated phosphoprotein , Mr 32 kDa ( DARPP-32 ), was identified initially as a major target for dopamine and protein kinase A (PKA) in striatum
Glausier et al., Neuroscience 2010 : Inhibition of PP1 occurs through PKA mediated phosphorylation of dopamine- and cAMP regulated phosphoprotein 32 kDa ( DARPP-32 ) or the related protein inhibitor-1 ( I-1 ), and the availability of DARPP-32 is essential to the functional outcome of D1R activation in the basal ganglia
Torres-Altoro et al., J Neurochem 2011 (Neurotoxicity Syndromes...) : CPF potentiated protein kinase A (PKA) dependent phosphorylation of the striatal protein dopamine- and cAMP regulated phosphoprotein of M ( r ) 32 kDa ( DARPP-32 ) and the glutamate receptor 1 (GluR1) subunit of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ( AMPA ) receptors in mouse brain slices
Slobodyansky et al., Am J Physiol 1995 : In the brain, dopamine, via protein kinase A (PKA) activation of dopamine- and cAMP regulated phosphoprotein ( DARPP-32 ), inhibits protein phosphatase 1 (PP1) activity and keeps Na ( + ) -K ( + ) -adenosinetriphosphatase (ATPase) in its phosphorylated inactive state